(Q54539122)

31 May 2018

title

Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. (English)

1 reference

31 May 2018

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

Yoshiki Hayashi

1

1 reference

31 May 2018

Hirohisa Nakamae

2

1 reference

31 May 2018

Takako Katayama

3

1 reference

31 May 2018

Takahiko Nakane

4

1 reference

31 May 2018

Hideo Koh

5

1 reference

31 May 2018

Mika Nakamae

6

1 reference

31 May 2018

Asao Hirose

7

1 reference

31 May 2018

Kiyoyuki Hagihara

8

1 reference

31 May 2018

Yoshiki Terada

9

1 reference

31 May 2018

Yoshitaka Nakao

10

1 reference

31 May 2018

Masayuki Hino

11

1 reference

31 May 2018

publication date

20 January 2012

1 reference

31 May 2018

published in

Leukemia & Lymphoma

1 reference

31 May 2018

volume

53

1 reference

31 May 2018

issue

6

1 reference

31 May 2018

page(s)

1084-1089

1 reference

31 May 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.647017

10.3109/10428194.2011.647017

21 January 2018

Identifiers

DOI

1 reference

31 May 2018

1 reference

31 May 2018